Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1356
Abstract: Both the combination of nivolumab + ipilimumab and single‐agent anti‐PD‐1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As the combination has a high rate of serious side effects, further analyses in randomized… read more here.
Keywords: combination; immunotherapy; combination nivolumab; clinical laboratory ... See more keywords
Abstract CT031: COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct031
Abstract: Introduction: COM701 is a novel first-in-class Immune checkpoint inhibitor (ICI) that binds with high affinity to poliovirus receptor related immunoglobulin domain containing (PVRIG) blocking its interaction with its ligand, PVRL2 and regulating the activity of… read more here.
Keywords: solid tumors; combination nivolumab; com701; arm ... See more keywords